In the past two trading sessions, shares of Allergan plc Ordinary Shares AGN 2.54% and Pfizer Inc. PFE 0.22% are headed in opposite directions.
The market clearly sees the decision to call off the Pfizer/Allergan merger as good news for Pfizer and bad news for Allergan. However, Barrons’ Johanna Bennett believes both stocks are now excellent buys.
“Both have potential blockbusters on the horizon yet Wall Street appears to be undervaluing their pipelines,” Bennett explains. She adds that Allergan and Pfizer currently trade at multiples of only 13.3 and 12.3, respectively, both deeply discounted from a historical perspective.
For Allergan, the sale of its generic drug business to Teva Pharmaceutical Industries Ltd (ADR) TEVA 1.77% will go a long way in solidifying the company’s debt-burdened balance sheet. The $40 billion pricetag on the generics business could virtually eliminate Allergan’s $42 billion in debt as of Dec. 31, or the company could decide to use a portion of the proceeds for share buybacks instead.
Pfizer, on the other hand, already yields…
Click here to continue reading
Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!
